Is there a generic for Opdivo?

Nivolumab is the generic name for the trade drug name Opdivo®. In some cases, health care professionals may use the generic name nivolumab when referring to the trade name Opdivo®. Nivolumab is a targeted therapy. It is a human programmed death receptor-1 (PD-1) blocking antibody.

Is Opdivo available in India?

Currently three drugs are available in India – pembrolizumab (Keytruda), nivolumab (Opdivo, Opdyta) and atezolizumab – that are approved by the Drug Controller General of India (DCGI) for stage-4 lung cancer patients.

How much longer do you live with Opdivo?

With a minimum follow-up of 6.5 years, median overall survival (OS) was 72.1 months with Opdivo plus Yervoy (95\% CI: 38.2-NR), the longest reported median OS in a Phase 3 advanced melanoma trial, 36.9 months with Opdivo (95\% CI: 28.2-58.7) and 19.9 months with the Yervoy group (95\% CI: 16.8-24.6).

How much does nivolumab cost?

Opdivo (nivolumab) is a member of the anti-PD-1 monoclonal antibodies drug class and is commonly used for Colorectal Cancer, Esophageal Carcinoma, Head and Neck Cancer, and others….Intravenous Solution.

Quantity	Per unit	Price
24 milliliters	$295.30	$7,087.13

Is Pembrolizumab better than nivolumab?

First, we compared pembrolizumab to nivolumab in patients with recurrent or advanced NSCLC. The survival analysis showed that pembrolizumab had a better ORR than nivolumab, but no significant difference in PFS was found between pembrolizumab and nivolumab.

Is nivolumab approved in India?

Nivolumab is approved for use as second line therapy in Renal cell cancers(RCC), and has become available for use in India since Oct 2016. There is no long term data about use of Nivolumab in Indian patients.

Is Opdivo the same as nivolumab?

Nivolumab is the generic name for the trade drug name Opdivo®. In some cases, health care professionals may use the generic name nivolumab when referring to the trade drug name Opdivo®. Drug type: Nivolumab is a targeted therapy. It is a human programmed death receptor-1 (PD-1) blocking antibody.

How long does nivolumab last?

Patients receive nivolumab intravenously (into a blood vein). Each dose takes about 60 minutes to complete. Patients usually receive nivolumab every two weeks unless their melanoma worsens or they experience unacceptable side effects.

Who company makes nivolumab?

Nivolumab is the generic name of the immunotherapy drug Opdivo, manufactured by Bristol-Myers Squibb. It works with your immune system’s T cells to recognize and attack cancer cells. It is FDA approved to treat non-small cell lung cancer but is also used as an off-label treatment for mesothelioma.

How long do you stay on nivolumab?

The average time for patients treated with ipilimumab/nivolumab to stay on therapy was about 2.5 months, but even among these patients, “two-thirds will stay in remission and do well,” he noted.

How effective is Nivolumab?

In the meta-analysis, nivolumab was associated with 9.6 months (95\% CI: 8.4–10.9) of overall survival and 2.6 months (95\% CI: 1.6–3.6) of progression-free survival. Conclusion: Very-low-certainty evidence suggested the real-world effectiveness of nivolumab was consistent with those observed in the clinical trials.